SynthesisThe Cochrane database of systematic reviews2009
Galantamine for dementia in people with Down syndrome.
Synthesis in The Cochrane database of systematic reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 5 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Quality of life measurement tools for people with dementia and intellectual disabilities: A systematic review.Journal of applied research in intellectual disabilities : JARID · 2023Pooled it
- Pharmacological Approaches to the Treatment of Dementia in Down Syndrome: A Systematic Review of Randomized Clinical Studies.Molecules (Basel, Switzerland) · 2022Pooled it
- Pharmacological interventions for cognitive decline in people with Down syndrome.The Cochrane database of systematic reviews · 2015Pooled it
- Donepezil for dementia in people with Down syndrome.The Cochrane database of systematic reviews · 2009Pooled it
- Memantine for dementia in people with Down syndrome.The Cochrane database of systematic reviews · 2009Pooled it
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Oral ELND005 (scyllo-Inositol) in Young Adults with Down Syndrome without Dementia.Journal of Alzheimer's disease : JAD · 2017Trial
- Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders.Annual review of pharmacology and toxicology · 2022Article
- Treating disorders across the lifespan by modulating cholinergic signaling with galantamine.Journal of neurochemistry · 2021Review
- Aging With Down Syndrome: The Dual Diagnosis: Alzheimer's Disease and Down Syndrome.American journal of Alzheimer's disease and other dementias · 2018Review
- Challenges faced in managing dementia in Alzheimer's disease in patients with Down syndrome.Degenerative neurological and neuromuscular disease · 2016Review
- Aging and down syndrome.Current gerontology and geriatrics research · 2012Article
- Neurological phenotypes for Down syndrome across the life span.Progress in brain research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer's dementia (AD) is the most common form of dementia in people with Down Syndrome (DS). Acetylcholine is a chemical found in the brain that has an important role in memory, attention, reason and language. Galantamine both inhibits the activity of acetylcholinesterase and increases the level of acetylcholine. Galantamine can improve cognitive function and slow the decline of AD in the general population over time. It is important to note that people with DS tend to present with AD at a much younger age than the normal population as well as having subtle differences in physiology (e.g. metabolism and heart rate) and may therefore have different requirements from the general population.
objectivesTo determine the effectiveness and safety of galantamine for people with DS who develop AD. SEARCH STRATEGY: CENTRAL, MEDLINE, EMBASE, CINAHL, PsycINFO, BIOSIS, SCI, SSCI and the NRR were searched up to October 2008. We contacted the manufacturers of galantamine as well as experts in the field, to ask about reports of unpublished or ongoing trials. SELECTION CRITERIA: Randomised controlled trials of participants with DS and AD in which treatment with galantamine was administered compared with a placebo group. DATA COLLECTION AND ANALYSIS: No study was identified which met inclusion criteria for this review. MAIN
resultsNo study was identified which met inclusion criteria for this review. AUTHORS'
conclusionsAs there are no included trials, recommendations cannot be made about galantamine for AD in DS. Well-designed, adequately powered studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.